


Express Mail Label No.: EV695509509US
Date of Deposit: November 15, 2005

Attorney Docket Number: 24852-501 CIP3



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Nicholas G. Bacopoulos *et al.*
SERIAL NO. : 10/650,025 **EXAMINER :** Phyllis G. Spivack
FILING DATE : August 26, 2003 **ART UNIT :** 1614
FOR : **METHODS OF TREATING CANCER WITH HDAC INHIBITORS**

MAIL STOP RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 and provide copies of the same.

This Information Disclosure Statement is being submitted concurrently with the filing of the Request for Continued Examination Under 37 CFR § 1.114. Accordingly, no fee or certification is believed required.


It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit
Account No. 50-0311, Reference No. 24852-501 CIP3.

Dated: November 15, 2005

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Charles E. Bell", written over a horizontal line.

Ivor Elrifi, Reg. No. 39,529

Charles E. Bell, Reg. No. 48, 128

Attorneys for Applicants

MINTZ, LEVIN, COHN, FERRIS

GLOVSKY AND POPEO, P.C.

Telephone: (617) 542-6000

Fax: (617) 542-2241

Please type a plus sign (+) in this box

+

PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Supplemental Form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/650,025
	Filing Date	08/26/03
	First Named Inventor	Bacopoulos
	Group Art Unit	1614
	Examiner Name	Phyllis G. Spivack
	Attorney Docket Number	24852-501 CIP3

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue or Pub. Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
	A21	RE38,506 E	04/20/04	Breslow, et al.	514	316	10/04/1991
	A22	6,905,669	06/14/05	DiMartino	424	9.1	04/24/2001
	A23	2003/0082666	05/01/03	Kammer, et al.	435	18	07/02/2002
	A24	2003/0235588	12/25/03	Richon, et al.	424	146.1	02/14/2003

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B11	WO	95/31977	Sloan-Kettering Institute for Cancer Research	November 30, 1995	X	
	B12	WO	98/55449	The University of Queensland	December 10, 1998	X	
	B13	WO	02/085400 A1	SuperGen, Inc.	October 31, 2002	X	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C84	O'Connor et al. (2001). <i>Journal of the American Society of Hematology</i> 611a, Abstract No. 2562.
	C85	Kelly, et al. (2003). <i>Clinical Cancer Research</i> 9:3578-3588.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.